Recent Transactions

09-Sep-21
$2.1 billion
United Kingdom flag
Target: 

easyJet plc

flag not available
Acquiror: 
N/A

Advising and acting as joint sponsor to UK-based easyJet plc, a leading low-cost European airline carrier, on its £1.2bn fully underwritten rights issue & $400m secured RCF

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

01-Oct-20
$2.6 billion
United Kingdom flag
Target: 

Rolls-Royce £2bn Fully Underwritten Rights Issue

flag not available
Acquiror: 
N/A

Advising Rolls-Royce on its Fully Underwritten £2bn Rights Issue, as part of a broader recapitalisation package

10-Jul-18
$1.1 billion
United Kingdom flag
Target: 

The AA plc

flag not available

Advised the AA plc, the UK’s largest roadside assistance provider, on the refinancing of £825mm of its senior secured facilities

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

31-Oct-17
$2.0 billion
South Africa, Switzerland flags
Target: 

Hirslanden Private Hospital Group

flag not available

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

US rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

30-Mar-15
$950 million
United Kingdom flag
Target: 

Quindell plc’s Professional Services Division

Australia flag
Acquiror: 
Slater and Gordon

Advised Slater and Gordon Limited, an ASX-listed international consumer law firm, on the acquisition of Quindell plc’s Professional Services Division, the UK’s leading personal injury law firm operating across the claims value chain, and associated A$890 million equity and A$375 million debt raisings

24-Feb-15
$NA
Luxembourg flag
Target: 

Azelis Group (majority owned by 3i)

United Kingdom flag
Acquiror: 
Funds advised by Apax Partners

Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners

19-Dec-11
$1.6 billion
United Kingdom flag
Target: 

The Miller Group

Advised The Miller Group, the UK’s largest private homebuilder, on the recapitalization of its balance sheet comprising a substantial new equity capital raising and a significant debt for equity swap

16-Jul-09
$NA
United Kingdom flag
Target: 

Pension Trustees of Galiform PLC

Advised the Pension Trustees of the Galiform PLC Defined Benefit Pension Scheme to negotiate a revised schedule of payments to fund its deficit

19-Mar-09
$349 million
United Kingdom flag
Target: 

Inchcape plc

Provided financial advice to Inchcape, the leading independent international automotive retailer, on its assessment of funding and strategic options, resulting in a significant rights issue to strengthen the balance sheet

show all